Table 1. Baseline characteristics.
| All (n = 100) | COVID-19 ARDS (n = 50) | Non-COVID-19 ARDS (n = 50) | p-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, year | 68.0 (63.0–72.5) | 68.0 (63.0–72.0) | 69.5 (62.0–73.0) | 0.497 |
| Age ≥ 65, n (%) | 66 (66.0) | 34 (68.0) | 32 (64.0) | 0.673 |
| Male, n (%) | 70 (70.0) | 34 (68.0) | 36 (72.0) | 0.663 |
| BMIa, kg/m2 | 23.8 (21.2–26.5) | 25.6 (23.0–27.8) | 22.1 (19.5–24.2) | <0.001 |
| Obesity, n (%) | 10 (10.0) | 4 (8.0) | 6 (12.0) | 0.505 |
| APACHE IIb | 25.0 (21.2–26.5) | 20.5 (16.0–25.0) | 29.0 (25.0–33.0) | <0.001 |
| Symptom to ICUc, days | 3.5 (1.0–7.0) | 5.0 (2.0–7.0) | 1.0 (0.0–6.0) | 0.001 |
| Comorbidity, n (%) | ||||
| Diabetes mellitus | 30 (30.0) | 17 (34.0) | 13 (26.0) | 0.383 |
| Chronic renal failure | 12 (12.0) | 2 (4.0) | 10 (20.0) | 0.014 |
| Cardiovascular disease | 29 (29.0) | 12 (24.0) | 17 (34.0) | 0.271 |
| Asthma | 2 (2.0) | 1 (2.0) | 1 (2.0) | 1.000 |
| COPDd | 9 (9.0) | 2 (4.0) | 7 (14.0) | 0.160 |
| Immunocompromised | 10 (10.0) | 0 (0.0) | 10 (20.0) | 0.001 |
| Laboratory data | ||||
| Leukocyte, 103/μL | 10.5 (6.5–13.5) | 9.8 (7.0–12.6) | 11.0 (5.2–15.9) | 0.647 |
| Neutrophil, % | 86.2 (75.8–91.5) | 88.5 (84.2–92.8) | 80.0 (54.0–89.4) | <0.001 |
| Lymphocyte, % | 6.4 (3.5–11.7) | 6.1 (3.3–8.9) | 7.3 (3.6–14.4) | 0.102 |
| C-reactive protein, mg/dL | 11.7 (6.4–16.6) | 9.4 (3.8–13.2) | 13.8 (8.4–21.9) | 0.004 |
| Platelet, 103/μL | 182.0 (124.5–237.0) | 182.5 (140.0–231.0) | 182.0 (80.0–246.0) | 0.759 |
| D-Dimer, μg/mL | 3.7 (1.5–10.0) | 3.4 (1.1–10.0) | 4.0 (1.7–9.7) | 0.296 |
| Creatinine, mg/dL | 1.0 (0.8–1.7) | 0.9 (0.7–1.1) | 1.3 (0.9–2.4) | 0.001 |
a BMI, body mass index
b APACHE II, acute physiology and chronic health evaluation
c ICU, intensive care unit
d COPD, chronic obstructive pulmonary disease.